Javascript must be enabled to continue!
A Model-Based Concurrent Specification Language over CML: Semantic Foundations
View through CrossRef
In this paper we address the problem of specification and design of concurrent systems. More accurately, we present the definition of a new specification language that is formal, wide-spectrum, model-based, concurrent, polymorphic and strongly implicitly typed. The language is built upon a concurrent, funtional and imperative programming language: Concurrent ML. Specification aspects are supported thanks to the addition of some specification constructs and also by allowing axioms to ML structures and signatures. The resulting specification language is thus highly expressive though it embodies a restricted number of concepts. We present here the motivations underlying the definition of such a language as well as the design choices. Furthermore, we introduce the specification and development methology and illustrate it on various examples. We will see that many specification styles are allowed: algebraic, applicative, state-based, concurrent applicative and concurrent imperative. We show that the language rests on secure theoretical foundations exemplified by formal syntactic and semantic definitions. The latter consists in a static semantics together with a dynamic semantics. The static semantics reconstructs not only principal types but also minimal side and communication effects. This is done thanks to an extension of the type and effect discipline. The language is also endowed with a dynamic denotational semantics. The underlying model is based on an extension of the acceptance trees model to handle value-passing, communication, assignment, sequencing, return of results and higher order objects.
Title: A Model-Based Concurrent Specification Language over CML: Semantic Foundations
Description:
In this paper we address the problem of specification and design of concurrent systems.
More accurately, we present the definition of a new specification language that is formal, wide-spectrum, model-based, concurrent, polymorphic and strongly implicitly typed.
The language is built upon a concurrent, funtional and imperative programming language: Concurrent ML.
Specification aspects are supported thanks to the addition of some specification constructs and also by allowing axioms to ML structures and signatures.
The resulting specification language is thus highly expressive though it embodies a restricted number of concepts.
We present here the motivations underlying the definition of such a language as well as the design choices.
Furthermore, we introduce the specification and development methology and illustrate it on various examples.
We will see that many specification styles are allowed: algebraic, applicative, state-based, concurrent applicative and concurrent imperative.
We show that the language rests on secure theoretical foundations exemplified by formal syntactic and semantic definitions.
The latter consists in a static semantics together with a dynamic semantics.
The static semantics reconstructs not only principal types but also minimal side and communication effects.
This is done thanks to an extension of the type and effect discipline.
The language is also endowed with a dynamic denotational semantics.
The underlying model is based on an extension of the acceptance trees model to handle value-passing, communication, assignment, sequencing, return of results and higher order objects.
Related Results
Hubungan Perilaku Pola Makan dengan Kejadian Anak Obesitas
Hubungan Perilaku Pola Makan dengan Kejadian Anak Obesitas
<p><em><span style="font-size: 11.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-langua...
A retrospective case-control study for Clinical Validation of mutated ZNF208 as a novel biomarker of fatal blast crisis in Chronic Myeloid Leukemia
A retrospective case-control study for Clinical Validation of mutated ZNF208 as a novel biomarker of fatal blast crisis in Chronic Myeloid Leukemia
Abstract
The hallmark of Chronic Myeloid Leukemia (CML) is Philadelphia chromosome t(9:22), which leads to formation of BCR-ABL1 fusion oncogene. BCR-ABL1 induces g...
Repositioning of FDA-approved anti-cancer drugs for fatal blast crisis CML by integrated high-throughput genomic and artificial intelligence-based drug discovery analyses of pan-leukemic genetic abnormalities: Implications in post-COVID-19 era
Repositioning of FDA-approved anti-cancer drugs for fatal blast crisis CML by integrated high-throughput genomic and artificial intelligence-based drug discovery analyses of pan-leukemic genetic abnormalities: Implications in post-COVID-19 era
Abstract
Background: Chronic Myeloid Leukemia (CML) is a type of cancer that affects the blood and bone marrow. Although treatable in initial chronic phase (CP-CML) and ac...
Clinical Validation Of ANKRD36 Mutations As A Novel Biomarker For Monitoring Early Progression and Timely Clinical Interventions In Blast Crisis CML
Clinical Validation Of ANKRD36 Mutations As A Novel Biomarker For Monitoring Early Progression and Timely Clinical Interventions In Blast Crisis CML
Background: Chronic Myeloid Leukemia (CML) is initiated in the bone marrow due to the chromosomal translocation t(9;22), resulting in the fusion oncogene BCR-ABL. Tyrosine kinase i...
Investigations on Clinical Validation of mutated ANKRD36 as a Novel Molecular Biomarker for Monitoring Early Progression and Timely Therapeutic Interventions in Blast Crisis CML
Investigations on Clinical Validation of mutated ANKRD36 as a Novel Molecular Biomarker for Monitoring Early Progression and Timely Therapeutic Interventions in Blast Crisis CML
Abstract
Background
Chronic Myeloid Leukemia (CML) is initiated in the bone marrow due to the chromosomal translocation t(9;22)...
Safety and Efficacy of Tgrx-678, a Potent BCR-ABL Allosteric Inhibitor in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant/Refractory Chronic Myeloid Leukemia (CML): Preliminary Results of Phase I Study
Safety and Efficacy of Tgrx-678, a Potent BCR-ABL Allosteric Inhibitor in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant/Refractory Chronic Myeloid Leukemia (CML): Preliminary Results of Phase I Study
Background:
TGRX-678 is a novel allosteric inhibitor of ABL kinases, specifically targeting the ABL Myristoyl Pocket (STAMP). In vitro data supports TGRX-678 targeti...
Nilotinib as the First Line Therapy in Managing Chronic Myelogenous Leukemia
Nilotinib as the First Line Therapy in Managing Chronic Myelogenous Leukemia
Abstrak: Leukemia mieloid kronis (chronic myeloid leukemia/CML) adalah penyakit klonal dari sel induk hematopoietik, secara sitogenetik ditandai dengan adanya kromosom Philadelphia...
Preferentially expressed genes in chronic myelogenous leukemia
Preferentially expressed genes in chronic myelogenous leukemia
Abstract
The predominant circulating cells in chronic myelogenous leukemia (CML) morphologically resemble normal myeloid precursors; however, certain characteristics...

